KyungDong Pharm home
Prescription Medicines

Bonseron Plus Tab.

Product Category
Osteoporosis treatment containing vitamin D3 taken once a week
Active Ingredients
Sodium Risedronate/Cholecalciferol
Appearance
Light orange, oval, film-coated tablet
Reimbursement Code
648103790
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredients:
Sodium risedronate 2.5 hydrate (USP) ------ 40.162mg (35mg as sodium risedronate)
Cholecalciferol Concentrate (Powder) (EP) -------- 56mg (5,600 IU as cholecalciferol)
- Additives (animal-derived ingredients): lactose hydrate (cow, milk), cholecalciferol concentrate (powder), cholecalciferol (sheep, wool), gelatin (cow, leather)
- Other additives: light anhydrous silicic acid, silicate microcrystalline cellulose, microcrystalline cellulose, magnesium stearate, Opadry II yellow (85F62513), crospovidone, hydroxypropyl cellulose

2. Effectiveness
Treatment and prevention of osteoporosis in postmenopausal women, treatment of osteoporosis in men

3. Dosage and dosage
1. Adults: Take 1 tablet of this drug orally once a week.
2. Elderly: There is no need to adjust the dose in elderly people (over 60 years old) because the bioavailability and pharmacokinetics of this drug are similar to those in young people.
3. Children: Safety and efficacy in children and adolescents have not been established.
4. Patients with renal impairment: There is no need to adjust the dose in patients with a creatinine clearance of more than 30ml/min. It is contraindicated in patients with severe renal impairment whose creatinine clearance is less than 30 ml/min.

Since food interferes with the absorption of this medicine, take it as follows to ensure sufficient absorption.
Take at least 30 minutes before breakfast or at any time during the day, at least 2 hours before or after eating or drinking.
To facilitate the medication reaching the stomach and reduce the possibility of esophageal irritation, take this medication in an upright position with a sufficient amount of pure water (170 to 230 ml). Taking this drug with other beverages, including mineral water, may decrease the absorption of this drug. This medication should not be chewed or sucked due to the potential for ulceration of the oropharynx.
And patients should not lie down for at least 30 minutes after taking the drug.
Patients should take calcium and vitamin D supplements if dietary intake is inadequate. Those at high risk of vitamin D deficiency, such as patients over 70 years of age, nursing home residents and people with chronic illnesses, may require additional vitamin D supplementation. Patients with gastrointestinal malabsorption may require higher doses of vitamin D, and measurement of 25-hydroxyvitamin D levels should be considered.
The recommended daily amount of vitamin D is 400 IU to 800 IU. Taken once a week, this medication provides a week's worth of 800 IU vitamin D per day.
If a patient forgets to take a dose on the scheduled day, they should take it on the day they remember, then resume the original dosing schedule. Do not take two tablets on the same day.

4. Precautions for use
1. Warning
This drug, like other bisphosphonate preparations, may cause local irritation to the upper gastrointestinal mucosa. In patients receiving oral bisphosphonates, esophageal adverse reactions such as esophagitis, esophageal ulcer, and esophageal erosion, along with bleeding, have been reported, and in rare cases, esophageal obstruction or perforation has been reported. In some patients, symptoms were severe and required hospitalization. Therefore, doctors should pay attention to all signs and symptoms that indicate an esophageal reaction, and instruct patients to stop taking the drug and consult a doctor if they experience symptoms such as dysphagia, dysphagia or retrosternal pain, or the development or worsening of heartburn. The risk of serious esophageal adverse reactions is much greater in patients who lie down after taking this medication, do not take this medication with a sufficient amount of water (170 to 230 ml), or continue to take this medication after symptoms of esophageal irritation appear. Therefore, it is very important to explain and understand the Dosage and Administration to the patient (see Dosage and Dosage). Treatment of this drug for patients who are unable to follow the prescribed dosage due to mental impairment should be conducted under appropriate supervision. Oral bisphosphonates can irritate the upper gastrointestinal mucosa, so caution should be exercised when administering them to patients with upper gastrointestinal diseases such as dysphagia, esophageal disease, gastritis, duodenitis, or ulcers. In post-marketing surveillance in foreign countries, cases of gastric ulcers and duodenal ulcers accompanied by some serious complications have been reported when administering oral bisphosphonates. This increased risk was not confirmed in controlled clinical trials.

2. Do not administer to the following patients.
1) Patients with esophageal abnormalities that delay esophageal emptying, such as esophageal stricture or atony
2) Patients with hypersensitivity to the main ingredients or excipients of this drug
3) Patients with hypocalcemia
4) Patients who cannot sit or stand upright for more than 30 minutes
5) Patients with severe renal impairment (those with creatinine clearance less than 30ml/min)
6) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

3. Adverse reactions
1) In the group administered 5mg risedronate sodium tablets shown in clinical trials, adverse reactions were similar to those in the placebo group. Most adverse reactions were mild or moderate, and no patient discontinued treatment due to them. The number of patients who developed severe adverse reactions in the placebo group was 24.9%, which was similar to the patients who received 5 mg risedronate sodium tablets (26.3%). The number of patients who discontinued the trial due to adverse reactions was 14.4% and 13.5% in the placebo group and patients administered 5 mg risedronate sodium tablets, respectively.
Adverse reactions with a frequency of more than 2% and occurring more frequently in the group administered 5 mg risedronate sodium tablets than in the placebo group are as follows.

※ Table: Refer to manual

Occasionally (0.1-1%) duodenitis and glossitis occurred. Rarely (<0.1%) abnormal results of each functional test have been reported.

Clinical examination values showed a slight decrease in asymptomatic blood calcium and phosphorus concentrations. In patients who received 5mg risedronate sodium tablets for 6 months, blood calcium concentration decreased by an average of 0.8% and blood phosphorus concentration decreased by an average of 2.7%. A total of 18 people (9 (0.5%)) in both the group that received 5 mg risedronate sodium tablets and the control group had blood phosphorus levels of 8 mg/dl or less. There were 14 patients with a blood phosphorus concentration of 2 mg/dl or less: 11 (0.6%) in the patients receiving 5 mg risedronate sodium tablets and 3 (0.2%) in the control group.

Endoscopic findings revealed that many of the patients participating in the clinical trial were already suffering from gastrointestinal diseases and were taking non-steroidal anti-inflammatory drugs or aspirin concomitantly. The investigator performed an endoscopic examination on patients complaining of moderate or severe gastrointestinal disease, and the same number of groups (75 each, 11.9%) who received 5 mg risedronate sodium tablets and the control group were examined. The cases in which the esophagus, stomach, and duodenum mucosa appeared normal in endoscopy were similar: 20% in the control group and 21% in the group receiving 5 mg risedronate sodium tablets. Patients who discontinued the trial and patients who showed abnormal findings during endoscopy were similar in the group that received 5 mg risedronate sodium tablets and the control group. There were more patients with mild duodenitis in the group receiving 5 mg risedronate sodium tablets, but the number of patients with duodenal ulcers was higher in the control group. Among patients showing these symptoms, the number of patients showing clinically important symptoms (perforation, ulceration, bleeding) was similar between the two groups (51% in the control group, 39% in the group administered 5 mg risedronate sodium tablets).

2) In a one-year double-blind, multicenter clinical trial comparing the administration of risedronate sodium tablets 5 mg once daily and the administration of risedronate sodium tablets 35 mg once a week in postmenopausal women, the overall safety and tolerability aspects of the two administration regimens were observed to be similar. Adverse reactions that occurred in more than 2% of patients during this clinical trial are as follows. Adverse reactions were recorded regardless of causal relationship with the drug.

※ Table: Refer to manual

3) In a one-year double-blind, multicenter clinical trial comparing risedronate sodium tablets 5 mg once daily and risedronate sodium tablets 150 mg once a month in postmenopausal women, the overall safety and tolerability aspects of the two administration regimens were observed to be similar. Adverse reactions that occurred in more than 2% of patients during this clinical trial are as follows. Adverse reactions were recorded regardless of causal relationship with the drug.

※ Table: Refer to manual

Acute phase reaction symptoms, in which fever or influenza-like symptoms appeared within the first 3 days of drug administration and lasted less than 7 days, were reported in 1.4% of the group administered risedronate sodium tablets 150 mg once a month and in 0.2% of the group administered risedronate sodium tablets 5 mg once a day.
The treatment discontinuation rate due to diarrhea was slightly higher in the group administered 150 mg risedronate sodium tablets once a month than the group administered 5 mg risedronate sodium tablets once daily (0.8% and 0.0%, respectively), and most of these digestive system adverse reactions occurred within the first few days of administration. Medication discontinuation due to vomiting symptoms occurred at the same level in both groups (0.3% and 0.3%, respectively).
There were no patients who experienced eye inflammation such as uveitis, scleritis, or iritis in the risedronate sodium tablets 150 mg group, but iritis occurred in two patients in the risedronate sodium tablets 5 mg tablets group.
As a result of laboratory tests, in the group administered 150 mg of sodium risedronate once a month and the group administered 5 mg sodium risedronate once a day, after 12 months, blood calcium increased by 0.3% and 0.1%, respectively, phosphate decreased by 2.3%, and PTH increased by 4.8% and 8.3%, respectively. In addition, after the first month of administration, the hypocalcemia incidence rate in the group administered 150 mg sodium risedronate once a month was slightly higher than the group administered 5 mg sodium risedronate once daily (2.2% and 0.2%, respectively), but the subsequent incidence rates of hypocalcemia were similar in the two administration groups (approximately 2%).

4) Osteoporosis in men
The results of a placebo-controlled clinical trial of 35 mg risedronate sodium tablets in 285 male patients with osteoporosis showed that it increased bone density, but there was no significant difference in the frequency of fractures. The overall safety and efficacy were similar to adverse reactions reported in osteoporosis clinical trials in postmenopausal women. Additionally, benign prostatic hyperplasia (5% in the risedronate sodium 35 mg group and 3% in the placebo group), nephrolithiasis (3% and 0%, respectively), and arrhythmia (2% and 0%, respectively).

5) Combination of 35 mg of sodium risedronate and 5,600 IU of cholecalciferol
In a 16-week multicenter, double-blind, active-controlled comparative study in postmenopausal women (158 people) and men (6 people) suffering from osteoporosis, a total of 21 adverse drug reactions were reported in the risedronate sodium and cholecalciferol combination group in a total of 18 patients, including gastrointestinal (12 cases) and musculoskeletal (6 cases) adverse drug reactions, and in the risedronate sodium group. A total of 24 adverse drug reactions were reported in 16 people, including those in the gastrointestinal system (10 cases) and musculoskeletal system (6 cases), and the safety profile of the combination of sodium risedronate and cholecalciferol was similar to that of sodium risedronate.

6) Complex of risedronate sodium 150mg and cholecalciferol 30000IU
In a 16-week multicenter, double-blind, active-controlled comparison study in postmenopausal women (150 people) suffering from osteoporosis, a total of 106 adverse drug reactions were reported in the risedronate sodium 150 mg and cholecalciferol 30,000 IU combination group in a total of 34 patients, including the musculoskeletal system (40 cases) and gastrointestinal system (32 cases), and in the risedronate sodium 150 mg group. A total of 82 adverse drug reactions were reported in 33 patients, including those related to the musculoskeletal system (32 cases) and gastrointestinal system (23 cases). The safety profile of the combination of sodium risedronate 150mg and cholecalciferol 30000IU was not statistically significantly different from that of sodium risedronate 150mg.

7) Foreign post-marketing surveillance (sodium risedronate single agent)
Stevens-Johnson syndrome (mucocutaneous ocular syndrome), severe skin reactions including toxic epidermal necrolysis, hypersensitivity reactions including angioedema, rash, and blisters, and skin reactions have been reported very rarely. Upper gastrointestinal abnormalities such as esophagitis, esophageal ulcer, and gastric ulcer have been reported. In the musculoskeletal system, bone pain, arthralgia, and myalgia were rarely reported. Eye inflammation, including iritis and uveitis, and jaw necrosis have been reported very rarely. Liver dysfunction and jaundice accompanied by significant elevations of AST (Aspartate aminotransferase), ALT (Alanine aminotransferase), and gamma-GTP (gamma-glutamyl transpeptidase) have been reported (frequency unknown). Osteonecrosis of the external auditory canal has been reported very rarely (bisphosphonate-based adverse reaction).

8) Domestic post-marketing survey
(1) Sodium risedronate single agent
As a result of a post-marketing use outcome survey conducted on 933 people over 6 years in Korea, the occurrence rate of adverse events was reported to be 18.86% (176/933 people, 320 cases) regardless of causal relationship, and among these, adverse drug reactions for which a causal relationship with sodium risedronate could not be ruled out were 6.65% (62 people/933 people, 85 cases), including indigestion. 1.71% (16 people/933 people, 17 cases), anorexia 0.64% (6 people/933 people, 6 cases), nausea 0.64% (6 people/933 people, 6 cases), muscle pain 0.54% (5 people/933 people, 5 cases), abdominal pain 0.43% (4 people/933 people, 4 cases), asthenia. It was reported in the following order: 0.43% (4 people/933 people, 4 cases), heartburn 0.32% (3 people/933 people, 3 cases), and solar plexus pain 0.32% (3 people/933 people, 4 cases). Unexpected adverse drug reactions were 1.29% (12 people/933 people, 15 cases), including loss of appetite at 0.64% (6 people/933 people, 6 cases), chest discomfort, palpitations, increased sweating, facial flushing, burning sensation, kidney stones, belching, hematuria, and fever at 0.11% (1 person/933 people, 1 case).
(2) Combination of 35 mg of sodium risedronate and 5,600 IU of cholecalciferol
As a result of a post-marketing survey conducted in Korea on 602 people who received this drug for 6 years for re-examination, the incidence of adverse events was reported to be 3.3% (20/602 people, 21 cases in total) regardless of causal relationship. The occurrence rate of unexpected adverse events was 0.5% (3/602 people, 3 cases in total) regardless of causal relationship, and 0.2% (1/602 people, 1 case) of fatty liver, increased serum alkaline phosphatase, and facial edema were each reported. Among these, facial edema was reported in 0.2% (1/602 people, 1 case) as an unexpected adverse drug reaction for which a causal relationship with this drug could not be ruled out.
As a result of clinical trials conducted after domestic marketing, 0.12% (1/806 people, 1 case) of unexpected adverse drug reactions were reported in 806 people who administered this drug: edema, facial edema, hair loss, and abnormal sense of smell.

4. General precautions
1) General information
It is also important to consider whether there are other causes of osteoporosis other than estrogen deficiency, aging, or glucocorticoid use.

Sodium risedronate
(1) Bisphosphonate drugs are associated with esophagitis and esophageal ulcer formation. Therefore, patients should pay attention to the above dosage. Additionally, doctors and pharmacists should emphasize the importance of dosage for patients with a history of esophageal disease.
(2) Hypocalcemia and other bone and mineral metabolism disorders (e.g., parathyroid dysfunction, vitamin D deficiency) must be treated before administering this drug. It is important for all patients to consume adequate amounts of calcium and vitamin D.
(3) Localized jaw bone necrosis has been rarely reported when administering oral bisphosphonate drugs. These symptoms were generally associated with local infection (including osteomyelitis) resulting in tooth extraction and/or delayed treatment (see Section 3. Adverse Reactions). Most of the cases of jaw necrosis reported to be related to bisphosphonate preparations occurred when intravenous bisphosphonate preparations were administered to cancer patients, but some also occurred in postmenopausal osteoporosis patients. Cancer, concomitant medications (e.g. chemotherapy, radiotherapy, corticosteroids), poor oral hygiene, concomitant diseases (e.g. periodontal disease and/or pre-existing dental disease, anemia, coagulopathy, infection), and smoking are known risk factors for jaw osteonecrosis. Patients who develop jaw bone necrosis should receive appropriate treatment from an oral surgeon. Dental surgery can make the situation worse. In patients requiring dental procedures, there are no available data showing that discontinuation of bisphosphonate treatment may reduce the risk for osteonecrosis of the jaw. A management plan for each patient should be established based on individual benefit/risk assessment based on the clinical judgment of the treating physician.
(4) Osteonecrosis of the external auditory canal has been reported in patients receiving bisphosphonates, including this drug. Risk factors include steroid use, chemotherapy, and/or local trauma and infection. The possibility of external auditory canal osteonecrosis should be considered in patients taking bisphosphonates who have chronic ear infections or symptoms such as ear discharge or pain.
(5) In post-marketing experience, severe and sometimes incapacitating bone, joint, and/or muscle pain has been rarely reported in patients receiving bisphosphonates. Bisphosphonate drugs also include this drug. Time to symptom onset varied from 1 day to several months after initiation of treatment. In most patients, symptoms were alleviated after discontinuation of treatment. In some of these patients, symptoms recurred when the same or a different bisphosphonate was readministered.

Cholecalciferol
(1) This drug should not be administered alone to treat vitamin D deficiency (usually, when the 25-hydroxyvitamin D level is less than 9 ng/mL).
(2) If the patient has insufficient calcium intake, supplements should be taken. Patients at greater risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, or chronically ill) may require higher doses of vitamin D supplements. Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplements and measurement of 25-hydroxyvitamin D levels should be considered. Weight-bearing exercise should be considered along with changes in certain habitual factors such as smoking and/or excessive drinking.
(3) Administration of vitamin D3 supplements to patients with diseases in which 1,25 dihydroxyvitamin D is uncontrolled and overproduced (e.g., leukemia, lymphoma, sarcoidosis) may worsen hypercalcemia and/or hypercalciuria. These patients should have their urine and serum calcium levels monitored.

2) Information to be provided to patients
(1) Drugs, foods, and beverages other than pure water containing polyvalent cations (calcium, magnesium, iron, aluminum, etc.) should not be administered simultaneously because they may interfere with the absorption of this drug. Therefore, to obtain the proven benefits of this drug, this drug should be administered at least 30 minutes before the first food intake of the day or at least 2 hours after food intake.
(2) In order to allow the drug to reach the stomach quickly and reduce the possibility of esophageal irritation, the patient must swallow this drug with a sufficient amount of water (170-230 mL) and should not lie down for at least 30 minutes after taking it and until after the first food intake of the day.
(3) This medicine should not be chewed or sucked due to the possibility of ulceration of the oropharynx. Patients should especially avoid taking this medication before going to bed or waking up. Patients must be informed that the risk of esophageal disorders increases if these precautions are not followed. If symptoms of esophageal disease appear (difficulty or pain in swallowing food, pain behind the sternum, heartburn occurs or worsens), the patient must be instructed to stop taking this medicine and consult a doctor.
(4) Doctors should consider administering calcium and vitamin D as adjuvant therapy when intake from food is insufficient. In particular, male and female patients receiving long-term systemic corticosteroid treatment should take appropriate amounts of calcium and vitamin D.
(5) Weight-bearing exercise should be considered along with changes in specific habit factors such as excessive smoking and drinking.
(6) Doctors must instruct patients to read the product instructions before treating this drug and to read it again each time a new prescription is prescribed.

3) Atypical, low-energy, or low-trauma fractures of the femoral shaft were reported in patients treated with bisphosphonates. These fractures can occur anywhere on the femoral stem, from the lesser trochanter to just above the supracondylar flare, and are essentially horizontal or short oblique in the absence of evidence of comminution. Because these fractures also occur in patients with osteoporosis who have not received bisphosphonate treatment, a causal relationship has not been established.
Atypical femur fractures most commonly occur after minimal or no trauma. This can occur both ways, and most patients report general pain, usually dull, aching thigh pain, in the affected area for weeks to months before a complete fracture occurs. A few reports mention the concurrent use of glucocorticoid treatment (e.g., prednisone) when fractures occur.
Any patient presenting with thigh or groin pain who has a history of exposure to bisphosphonates should be suspected of having an atypical fracture and evaluated to rule out an incomplete femur fracture. Patients presenting with an atypical fracture should also be evaluated for signs and symptoms of fracture in the contralateral limb. Discontinuation of bisphosphonate therapy should be considered while awaiting individual benefit/risk assessment.

5. Interaction
<Sodium risedronate>
1) Separate drug interaction studies have not been conducted on this drug. Among women participating in a phase 3 clinical trial for the treatment of postmenopausal osteoporosis, 31% took aspirin, 48% took NSAIDs, and 21% took H2 antagonists and/or proton pump inhibitors. The occurrence of upper gastrointestinal adverse reactions in patients who regularly took aspirin or NSAIDs for more than 3 days a week was similar in the test and control groups, and similar results were also observed in patients who took H2 antagonists and/or proton pump inhibitors.
2) If necessary, it can be combined with hormone replacement therapy.
3) Concurrent administration of calcium supplements, antacids, and oral medications containing polyvalent cations (calcium, magnesium, iron, aluminum, etc.) interferes with the absorption of this drug.
4) This drug is not systemically metabolized and does not induce or inhibit cytochrome P-450 enzymes. The protein binding rate in human plasma is about 24%, and according to animal experiments, about 60% was distributed to bones. The remainder is renally excreted unmetabolized.

<Cholecalciferol>
1) Drugs that can inhibit cholecalciferol absorption
Olestra, mineral oil, orlistat, and bile acid removers (e.g. cholestyramine, colestipol) may interfere with vitamin D absorption. Additional supplementation of vitamin D should be considered.
2) Drugs that can enhance the catabolism of cholecalciferol
Anticonvulsants, cimetidine, and thiazides may enhance the catabolism of vitamin D. Additional supplementation of vitamin D should be considered.

6. Administration to pregnant and lactating women
<Sodium risedronate>
1) Although there have been no studies on pregnant women, it has been reported in animal tests that maternal hypocalcemia and fetal ossification effects may occur during the delivery period.
2) Considering the importance of this drug to nursing mothers, administration of this drug should be discontinued or breastfeeding should be discontinued.
3) When more than 16 mg/kg/day of this drug (converted to body surface area (mg/m2), approximately 5.2 times the human dose of 30 mg/day) was administered to rats during pregnancy, the number of live births decreased, and non-ossification and incomplete ossification of the sternal segment increased. In addition, when administered at 80 mg/kg/day, the birth weight decreased, and when administered at 7.1 mg/kg/day, the number of fetuses with incomplete ossification of the sternal segment and skull increased statistically significantly. In fetuses delivered at doses exceeding 3.2 mg/kg/day, cleft palate was observed at a low incidence.
When administered to rabbits at up to 10 mg/kg/day during pregnancy, no significant fetal ossification effect occurred. However, at 10 mg/kg/day, 1 of 14 pups was miscarried and 1 was born prematurely. Similar to other bisphosphonate preparations, when administered to rats at 3.2 mg/kg/day (1 times the human dose) during mating and pregnancy, perinatal hypocalcemia and death of the mother were observed.
This drug is detected in lactating rats within 24 hours after drug administration and is secreted through milk.

<Cholecalciferol>
1) There is no data on cholecalciferol (vitamin D3). When ergocalciferol (vitamin D2) was administered to pregnant rabbits in high doses (more than 10,000 IU once every two days), the rate of miscarriage and fetal aortic stenosis increased. Administration of 40,000 IU of vitamin D2 per day to pregnant rats resulted in neonatal death, reduced fetal weight, and impaired osteogenesis of long bones after birth.
2) Cholecalciferol and its active metabolite are transferred into breast milk.

7. Administration to children
Safety and efficacy in children have not been established.

8. Administration to elderly people
There is no difference in safety and efficacy between elderly and young patients.

9. Treatment in case of overdose
<Sodium risedronate>
1) A decrease in blood calcium and phosphorus may be expected in some patients due to significant overdose. These patients may develop signs and symptoms of hypocalcemia. To reduce the absorption of this drug, milk or an antacid containing calcium should be administered.
2) In case of significant overdose, gastric lavage may be considered to remove unabsorbed drug. Effective, standardized methods to effectively treat hypocalcemia restore physiological amounts of ionized calcium and reduce the signs and symptoms of hypocalcemia.

<Cholecalciferol>
1) A single high-dose (4 mg/kg) oral administration of calcitriol, a hormonal metabolite of cholecalciferol, to mice resulted in a significant mortality rate.
2) There were no reports of toxicity when 600,000 IU of ergocalciferol (vitamin D2) was administered intermittently (once or twice a year) as a single dose, but dosage information on cholecalciferol related to acute toxicity is limited. Signs and symptoms associated with vitamin D toxicity include hypercalcemia, hypercalciuria, anorexia, nausea, vomiting, polyuria, polydipsia, weakness, and lethargy. Patients with suspected vitamin D toxicity should have serum and urine calcium levels monitored. Standard treatment for patients with severe hypercalcemia includes limiting dietary calcium intake, hydration, and systemic glucocorticoid administration. Dialysis to remove vitamin D is not effective.

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

11. Pharmaceutical equivalence test information
A. As a result of measuring the blood risedronic acid and cholecalciferol in the blood of 53 healthy adults by administering one tablet each on an empty stomach in a 2×2 cross-over study of the test drug Altotone Plus tablets [Yooyoung Pharmaceutical Co., Ltd.] and the control drug Resenex Plus tablets [Hallim Pharmaceutical Co., Ltd.], when the comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the AUCt for risedronic acid was The 90% confidence interval of the mean difference was within log 0.8 to log 1.25, and the 90% confidence interval of the mean difference for Cmax was outside log 0.8 to log 1.25. However, since the average difference in Cmax is within log 0.9 to log 1.11, and the submitted comparative dissolution test data are equivalent, it has been proven to be biologically equivalent in accordance with the proviso to Article 17, Paragraph 3 of the Pharmaceutical Equivalence Test Standards. In addition, cholecalciferol was proven to be biologically equivalent as the 90% confidence interval of the mean difference between AUCt and Cmax was within log 0.8 to log 1.25.

※ Table: Refer to manual

B. In accordance with the proviso to Article 17, Paragraph 3 of the Pharmaceutical Equivalence Test Standards, comparative dissolution test data were submitted between the test drug Altotone Plus Tablets [Yooyoung Pharmaceutical Co., Ltd.] and the reference drug Resenex Plus Tablets [Hallim Pharmaceutical Co., Ltd.], and the dissolution patterns were equivalent to the reference drug.
Note 1. This drug was manufactured by Yuyoung Pharmaceutical Co., Ltd. using the same raw materials as Altotone Plus Tablet and the entire process was contracted to Yuyoung Pharmaceutical Co., Ltd. using the same manufacturing method.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
4 tablets/PTP

7. Period of use
36 months from date of manufacture

Product Updates

Total 2items

No.Product NameDetailsDate of ChangeDownload
2Bonseron Plus Tab.Bonseron Plus Tablet (Precautions for use)2017.03.16HWP7_Bonseron Plus Tablet.hwp
1Bonseron Plus Tab.Bonseron Plus Tablet (Precautions for use)2016.11.21HWP11_Bonseron Plus Tablet.hwp